Pages tagged “FDA”
-
ACS – MCRAA Joint Comments on FDA Proposed Research Guidelines
ACS – MCRAA Joint Comments on FDA Proposed Research Guidelines
The Medical Cannabis Research Advocacy Alliance (MCRAA) appreciates the opportunity to provide comments in response to the US Food and Drug Administration (FDA)’s Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Draft Guidance for Industry; Availability 85 FR 44305 (July 22, 2020).
Written by Jordan Tishler
February 25, 2024 -
CBD RFI Response from Association of Cannabinoid Specialists
CBD RFI Response from Association of Cannabinoid Specialists
Recently ACS was asked to provide a response to the request for information from Congress with regard to regulation of CBD and derivatives. The full response is available below and in pdf form here.
Written by Jordan Tishler
August 22, 2023